Three Things About to Move Johnson & Johnson (JNJ) Stock

3. Post-2008 drug launches
I find this next statistic fascinating. Products launched since 2009 accounted for just 17% of pharmaceutical sales last year, but will grow to account for nearly half of sector sales by 2017. The trend will be driven by Invokana, Simponi, autoimmune drug Stelara, Zytiga for prostate cancer, anticoagulant Xarelto, and multidrug resistant tuberculosis therapy Sirturo, among others. That gives Johnson & Johnson (NYSE:JNJ) stock a healthy stable of near-perpetual catalysts in the next five years — and doesn’t include anticipated launches in the late-stage pipeline.

Foolish bottom line
You may overlook Johnson & Johnson for its broad operations throughout the health-care industry, but make no mistake about it: Pharmaceutical sales will continue to drive the stock higher. The company’s focus on biologics in the pipeline — and their cumulative success in clinical trials — will continue to pay dividends for years to come. Literally. I believe this company is a solid pharma play with a bright future, but you may still be wondering…

The article 3 Things About to Move Johnson & Johnson Stock originally appeared on Fool.com.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson (NYSE:JNJ).

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.